Vicept Therapeutics has reported positive results from a Phase II clinical trial evaluating V-101 cream, a topical cream for the treatment of facial redness known as Type I Rosacea (ETR).

The results showed a statistically significant improvement in the primary endpoint, which was defined as a reduction in facial erythema over an eight-hour period in patients with ETR, compared to placebo

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

In addition, V-101 demonstrated a safety profile similar to the placebo cream, without any evidence of “rebound” or tachyphylaxis.

The prospectively randomised, multi-centred, double-blinded and placebo-controlled trial was designed to assess the dose-response relationship of four concentrations of V-101 cream versus.

A total of 183 patients with moderate to severe erythema were enrolled at seven investigational centres across the US.

Patients were divided among five groups and self-administered one of four concentrations of V-101 cream or placebo cream once daily for 28 days.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.